Talk:Small cell lung cancer

From - A Hematology Oncology Wiki
Jump to navigation Jump to search


Hi, could you please add Caspian study?

DO you think durvalumab will become more attractive ICP over atezolizumab due to more liberal scheduling q4 weeks?

This has been added. Hard to know which will become more attractive - probably a good case for a network meta-analysis to try to estimate which is the more effective and the less toxic! Jeremy L. Warner MD, MS (talk) 20:11, 2 November 2019 (EDT)